Biotech companies must have the right people to succeed. Bold science, however exciting, is not enough. The Alpine BioVentures team brings our unique expertise to every investment. We have been involved in every facet of drug development and have guided products all the way from the discovery stage to regulatory approval. We have long-standing relationships with big pharma, big biotech, and Wall Street to help our companies reach their full potential.
Dr. Mitchell H. Gold has a lifelong commitment to helping patients with cancer, stemming from the loss of his 26-year old mother to metastatic breast cancer when he was four years old. This loss served as the catalyst for Dr. Gold’s career in medicine and desire to transform scientific breakthroughs into a reality for patients.
As CEO of Dendreon Corporation, Dr. Gold and his team developed a new class of therapies called active cellular immunotherapy (ACI), designed to engage a patient’s own immune system against cancer. Dendreon ushered in an entirely new era in cancer treatment with the FDA approval of PROVENGE® (sipuleucel-T), in April 2010.
Prior to joining Alpine Immune Sciences, Dr. Jay Venkatesan was the executive vice president and general manager of Oncothyreon, Inc (now Cascadian Therapeutics) from August 2014 to May 2015 following Oncothyreon’s acquisition of Alpine Biosciences, where he served as co-founder and CEO. Previously, Dr. Venkatesan was the founder, portfolio manager, and managing director of Ayer Capital Management, a global healthcare long-short equity fund. Prior to that, he served as a director at Brookside Capital Partners, the hedge fund group affiliated with Bain Capital, where he co-managed healthcare investments and evaluated public and private investments in all healthcare subsectors. Earlier in his career, Dr. Venkatesan was involved in healthcare venture investing at Patricof & Co. Ventures (now Apax Partners) and consulting at McKinsey & Company.
David Miller brings 15 years of life sciences experience to Alpine BioVentures. As the former CEO of the independent research firm Biotech Stock Research, Mr. Miller’s specialty is in-depth research into the science, operations, management, and market potential of both cutting-edge science and established development-stage biotechnology companies.
Miller also co-founded with Dr. Alan Leong the Entrepreneur’s Workshop curriculum at the University of Washington – Bothell campus. The Entrepreneur’s Workshop generated stunning success for the campus and surrounding community with over 90 companies launched – generally acknowledged as the highest launch rate for an undergraduate entrepreneurship program in the nation.
Dr. Remy Durand joins Alpine BioVentures with over 10 years of experience in life sciences research, consulting, and investing.
Prior to Alpine BioVentures, Dr. Durand was a Vice President on the life sciences investment team at Frazier Healthcare Partners, one of the first dedicated healthcare investment firms. During his time at Frazier, he was a board observer or director on multiple investments including Alpine Immune Sciences (NASDAQ: ALPN), Aptinyx (NASDAQ: APTX), and Scout Bio. Earlier in his career, he was an investment professional at GE Ventures Healthcare and spent time as a management consultant with LEK Consulting, a premier strategic advisor to the life sciences industry. Dr. Durand is also currently the Vice President of Business Development at Alpine BioVentures portfolio company Alpine Immune Sciences (NASDAQ: ALPN).
